U.S. to charge Teva in generic drugs price-fixing probe, report says


Adds background on investigation

Aug 25 (Reuters) - The U.S. Justice Department is preparing to charge Teva Pharmaceutical Industries Ltd TEVA.TA with conspiring with competitors to raise prices for generic drugs, Bloomberg Law reported on Tuesday, citing a person familiar with the matter.

The decision follows Teva's refusal to agree to a settlement that would have required paying a criminal penalty and admitting wrongdoing, the report said. (

Teva declined to comment on the report.

The Justice Department has been investigating allegations the company colluded with other drugmakers to push up the prices of widely used pharmaceuticals, including a high cholesterol drug.

Lawyers for Teva had met with Justice Department officials in the spring to discuss a potential settlement, but Teva walked away from the talks in April, the New York Times reported in May.

(Reporting by Diane Bartz in Washington and Mrinalika Roy in Bengaluru; Editing by Vinay Dwivedi and Paul Simao)

((; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.